biostudies-literatureDobrowolski CArthritis Society, Young Investigator AwardProvince of Ontario Early Research AwardNCATS NIH HHSCanadian Rheumatology Association–Arthritis Society Clinician Investigator AwardDepartment of Medicine, University of TorontoNational Center for Advancing Translational ScienceLupus Research AllianceNational Institutes of HealthLupus Ontario and Schroeder Arthritis InstituteArthritis Society of Canada, Canadian Institutes of Health Research, Physician’s Services Incorporated1860-1869https://www.ebi.ac.uk/biostudies/studies/S-EPMC10152298biostudies-literatureUnknown62(5)<h4>Objectives</h4>Cognitive dysfunction (CD) is a common manifestation of SLE that can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-CD. This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies.<h4>Methods</h4>Consecutive adult SLE patients presenting to a single healthcare center were considered for participation. The ACR neuropsychological battery for SLE was administered to consenting patients at 0, 6 and 12 months. Scores were compared with age- and sex-matched controls. Primary outcome was CD, defined as a z-score ≤-1.5 in two or more cognitive domains. Mixed-effects logistic regression models wRheumatology (Oxford, England)Association of mycophenolate and azathioprine use with cognitive function in systemic lupus.PMC10152298UL1TR002556UL1 TR002556Diaz Martinez JPWither JEKatz PDobrowolski CRuttan LChoi MYSu JKakvan MBingham KSTouma ZMcGinley JBeaton DEGreen RAnderson NPutterman CFazzari MBonilla DFritzler MJTartaglia MCfalseAssociation of mycophenolate and azathioprine use with cognitive function in systemic lupus.<h4>Objectives</h4>Cognitive dysfunction (CD) is a common manifestation of SLE that can have detrimental consequences for those affected. To date, no treatments have been approved for SLE-CD. This study aims to assess the association of azathioprine (AZA) and mycophenolate (MMF) use with SLE-CD, given that these medications have demonstrated neuroprotective qualities in prior studies.<h4>Methods</h4>Consecutive adult SLE patients presenting to a single healthcare center were considered for participation. The ACR neuropsychological battery for SLE was administered to consenting patients at 0, 6 and 12 months. Scores were compared with age- and sex-matched controls. Primary outcome was CD, defined as a z-score ≤-1.5 in two or more cognitive domains. Mixed-effects logistic regression models w2023-01-01T00:00:00Z2023 May2026-07-14T23:02:14.588Z2025-04-06T00:47:21.925ZS-EPMC101522983613579210.1093/rheumatology/keac540